Oncolytics Biotech ($ONCY) Stock Hub

Executive summary: what matters most now

Oncolytics Biotech is no longer best understood as a broad oncolytic-virus research company running many proof-of-concept programs. The company has narrowed its operating strategy around pelareorep as a systemic immune-priming therapy for gastrointestinal tumors, with the clearest internally funded path now running through randomized colorectal cancer development and a planned pivotal anal cancer program. Pancreatic cancer remains scientifically and commercially important, but the company has stated that it does not expect to finance the proposed Phase 3 program on its own without a partner.

The clinical case is unusual. Pelareorep has produced encouraging response, durability and survival signals in several difficult tumor types, including two randomized metastatic breast cancer studies and multiple pancreatic cancer datasets. In second-line KRAS-mutant MSS colorectal cancer, the company has reported a 33% objective response rate, 16.6-month median progression-free survival, 19.5-month median duration of response and 27-month median overall survival. In advanced anal cancer, company-reported response rates have clustered around 30%, including complete responses in heavily pretreated patients. These outcomes are the reason the FDA has now granted multiple Fast Track designations and engaged with Oncolytics on potential registration-directed designs.

The central limitation is equally important: the most valuation-sensitive colorectal and anal cancer signals were generated in small cohorts and were compared largely with historical benchmarks. Historical comparisons can be distorted by patient selection, treatment era, supportive care and many other variables. REO 033 is therefore the most important trial in the company’s history to date because it is designed to test whether the colorectal signal survives a prospective, randomized comparison against a contemporary control arm.

Company overview: what Oncolytics is today

Oncolytics Biotech is a clinical-stage biotechnology company developing a single principal platform asset, pelareorep, formerly known as REOLYSIN. Pelareorep is a proprietary formulation of a naturally occurring double-stranded RNA reovirus designed for intravenous administration. Unlike locally injected oncolytic viruses, pelareorep is intended to reach tumors systemically, selectively replicate in permissive cancer cells and stimulate both innate and adaptive anti-tumor immune responses.

The company was founded in Alberta in 1998 and spent much of its history building clinical experience across solid tumors. Its corporate and development identity evolved from direct tumor lysis toward a broader immune-oncology thesis: pelareorep may act as an immune-priming backbone that alters the tumor microenvironment and increases the effectiveness of chemotherapy, checkpoint inhibitors and potentially targeted agents.

On March 31, 2026, Oncolytics completed its domestication from Canada to Nevada and became a U.S. domestic issuer, while retaining a Calgary office and making San Diego its headquarters. The common stock remains listed on the Nasdaq Capital Market under ONCY. The company voluntarily delisted from the Toronto Stock Exchange in August 2025.

How pelareorep is designed to work

Pelareorep’s investment thesis rests on more than direct viral killing. The company describes a multi-layer mechanism in which the virus selectively replicates in susceptible cancer cells, triggers inflammatory signaling and helps expand immune cells capable of recognizing viral and tumor antigens. This matters because many gastrointestinal tumors—especially pancreatic ductal adenocarcinoma and most microsatellite-stable colorectal cancers—are poorly responsive to existing immunotherapy.

Pelareorep has been combined with several chemotherapy backbones and checkpoint inhibitors, including atezolizumab, pembrolizumab, nivolumab and retifanlimab. The platform argument is that pelareorep is not necessarily a stand-alone cytotoxic therapy; it may be most useful as a component that improves the activity and durability of established treatment regimens.

Safety and clinical exposure

The 2025 Form 10-K states that more than 1,200 patients had received pelareorep across the development program. Company disclosures characterize the safety profile as generally manageable, with flu-like events such as fever, chills, fatigue, headache, muscle aches, nausea and gastrointestinal symptoms among the most common treatment-related effects. Safety must still be evaluated within each combination regimen, because chemotherapy and checkpoint inhibitors contribute their own toxicities and a larger registrational program may identify less common events.

Oncolytics history: from REOLYSIN to a GI registration strategy

Pipeline snapshot: active programs versus optionality

A pipeline table can make Oncolytics look broader than its current financing capacity. The more accurate distinction is between programs the company is actively operating, programs with a defined regulatory concept but no confirmed active pivotal trial, and programs whose next major step depends on external funding or a partner.

Colorectal cancer: REO 033 is the central value-creation test

Why RAS-mutant MSS colorectal cancer is difficult

Most microsatellite-stable metastatic colorectal cancers do not respond meaningfully to checkpoint-inhibitor monotherapy. RAS mutations further define a biologically important population with limited targeted options outside specific variants and treatment sequences. In the second-line setting after oxaliplatin-based therapy, FOLFIRI plus bevacizumab is a common treatment backbone, but response rates and durability are generally modest.

The signal-generating REO 022 dataset

Oncolytics’ colorectal thesis originated from an earlier study evaluating pelareorep with FOLFIRI and bevacizumab. In the KRAS-mutant MSS second-line subgroup, the company reported:

The magnitude and internal consistency of these endpoints are the strongest part of the colorectal thesis. Response rate, durability, progression-free survival and overall survival all moved in the same direction. Translational work also reported expansion of KRAS-mutant–specific T-cell activity, offering a plausible mechanistic bridge between pelareorep exposure and clinical outcomes.

REO 033 Part A: the active randomized study

REO 033 is an open-label, randomized, multicenter Phase 2 study in patients with RAS-mutated, MSS metastatic colorectal cancer that progressed after one prior oxaliplatin-based regimen. Approximately 60 patients are planned to be randomized 1:1:

• Experimental arm: pelareorep + FOLFIRI + bevacizumab.
• Control arm: FOLFIRI + bevacizumab.
• Primary endpoint: objective response rate by RECIST 1.1.
• Secondary endpoints: progression-free survival, overall survival, safety and tolerability.

ClinicalTrials.gov lists an actual study start of April 30, 2026, estimated enrollment of 60 and recruiting status. On July 13, the company said approximately half of the planned sites were expected to be active by the end of July, the remaining sites by the end of August, and more than 20 potential patients had been pre-identified across centers. Pre-identification is not the same as enrollment, but it is a useful operational signal because small oncology trials can be delayed by site activation and eligibility screening.

The proposed registrational Part B

Oncolytics plans a Type D meeting with the FDA in the first half of August 2026 to discuss adding a larger, registration-directed Part B to REO 033. The company proposes retaining the core randomized design, increasing enrollment and adding blinded independent central review. Management believes the structure could preserve the existing trial infrastructure and potentially support accelerated approval based on an earlier endpoint while continuing toward traditional approval.

This is an ambitious and potentially efficient strategy, but three points require discipline:

1. The FDA has not yet publicly endorsed the final Part B design.
2. Accelerated approval would still require a compelling surrogate endpoint, adequate safety, manufacturing readiness and an overall benefit-risk package acceptable to the agency.
3. Randomized Part A data could weaken the thesis if the control arm performs better than historical benchmarks or if pelareorep does not create clear separation.

Anal cancer: strong unmet need, Fast Track and a changing pivotal design

The treatment context changed in 2025

In May 2025, the FDA approved retifanlimab with carboplatin and paclitaxel as first-line therapy for adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. The agency also approved retifanlimab monotherapy for disease progressing after, or intolerant to, platinum chemotherapy. This created a new first-line standard and changed the logical place for pelareorep.

Oncolytics is now targeting patients whose disease progresses after contemporary first-line treatment that can already include both chemotherapy and checkpoint blockade. The company argues that there is no specifically approved therapy for patients who progress after that current first-line combination. The population is smaller than broad first-line disease, but the unmet need is clearer and may allow a more focused development path.

GOBLET Cohort 4 data

GOBLET Cohort 4 evaluated pelareorep plus atezolizumab in relapsed, unresectable anal cancer. Company disclosures have described:

• Approximately 30% objective response rate in second-line or later patients.
• In a January 2026 third-line analysis, four responses among 14 evaluable patients, including two complete responses and two partial responses.
• Median duration of response near 17 months in the third-line analysis.
• In the broader data package cited for the July Fast Track, median duration of response around 15.5 months and 12-month overall survival of 82%.

Complete responses and long response duration in a heavily pretreated population are clinically interesting. However, the dataset is small, single-arm and compared with historical checkpoint-inhibitor data. The apparent difference could narrow in a randomized trial, especially as standards and patient selection evolve.

From a proposed single-arm study to a randomized pivotal strategy

Before the April 2026 FDA meeting, Oncolytics said it planned to discuss a single-arm registrational approach. After the Type C meeting, the company reported alignment on a randomized controlled pivotal study comparing pelareorep plus a checkpoint inhibitor with a control arm. Management said the same study could potentially support accelerated and full approval at different time points.

This evolution is important. A randomized design raises cost and execution complexity but improves evidentiary credibility. It also suggests the agency expects controlled evidence rather than accepting the small historical-comparison dataset as sufficient on its own.

July 20, 2026 Fast Track designation

The new Fast Track designation confirms that the FDA recognizes the seriousness of the condition and the potential unmet need of the targeted population. It may allow more frequent regulatory interactions, rolling submission of a future Biologics License Application and eligibility for Priority Review if the applicable criteria are met. It does not mean the pivotal protocol is funded, activated or guaranteed to produce an approvable result.

Pancreatic cancer: important evidence, but the Phase 3 is partner-dependent

Pancreatic ductal adenocarcinoma was the central Oncolytics narrative before the 2026 strategy pivot. The biological rationale is strong because pancreatic tumors are typically immune-suppressed and poorly responsive to checkpoint therapy. Pelareorep could be valuable if it makes the tumor environment more inflamed and improves immune-cell access or activity.

GOBLET Cohort 1

The first-line GOBLET cohort combined pelareorep, atezolizumab, gemcitabine and nab-paclitaxel. In 13 evaluable patients, early reporting showed a 69% objective response rate, later updated to a confirmed/overall response framework around 62%, with a disease control rate of 85%. The company also reported median progression-free survival around 7.2 months and interim median overall survival around 10.6 months.

These results were encouraging, particularly the response rate, but the cohort was small and lacked a concurrent control. The regimen also contained four agents, making it difficult to isolate the contribution of pelareorep or atezolizumab.

Earlier randomized evidence

The NCI-sponsored randomized study often referred to as NCI-8601 compared carboplatin/paclitaxel-based therapy with or without pelareorep in advanced pancreatic cancer. Conventional median endpoints did not show a dramatic broad advantage, but longer-term survival appeared numerically better in the pelareorep arm. Oncolytics has used pooled and longer-term survival analyses to argue that pelareorep’s benefit may be expressed more clearly in the tail of the curve than in early response or median outcomes.

This is a plausible but still unproven interpretation. Tail-of-curve effects require careful analysis because small numbers at later time points can produce unstable percentages.

GOBLET Cohort 5: separating the checkpoint contribution

GOBLET Cohort 5 randomizes patients to modified FOLFIRINOX plus pelareorep with or without atezolizumab. The design is intended to clarify whether checkpoint inhibition contributes meaningfully to the combination. The cohort is supported by a PanCAN award of up to $5 million. Oncolytics determined in Q1 2026 that enough patients had enrolled for analysis and expects a preliminary analysis in the second half of 2026 once survival data mature sufficiently.

FDA-aligned Phase 3 concept

Following a Type C meeting in late 2025, the company described a potential first-line Phase 3 with:

• Gemcitabine + nab-paclitaxel control.
• Gemcitabine + nab-paclitaxel + pelareorep.
• An optional third arm adding a checkpoint inhibitor.
• Overall survival as the primary endpoint, with PFS and response rate as secondary endpoints.

A pancreatic partnership would be one of the most material possible corporate catalysts because it could validate the asset, provide non-dilutive funding and restore a major indication to active development. Until a signed agreement exists, however, partnership language should be treated as optionality rather than a forecast.

Breast cancer and legacy evidence: clinically relevant, operationally deprioritized

Metastatic breast cancer produced some of pelareorep’s strongest randomized evidence and should not be erased from the history simply because the company is now focused on gastrointestinal tumors. At the same time, the breast program is not a near-term internally funded catalyst.

IND.213

In a randomized Phase 2 study, pelareorep plus paclitaxel did not create a major progression-free survival advantage in the full population, but the company reported a meaningful overall-survival difference, including a larger effect in the HR-positive/HER2-negative subgroup. The divergence between PFS and OS helped establish the idea that immune effects may emerge over time and may not be captured fully by early radiographic endpoints.

AWARE-1

AWARE-1 was a small window-of-opportunity study in early-stage breast cancer designed to examine tumor and immune changes over a short exposure period. It met its translational primary endpoint and reported that pelareorep, alone and with atezolizumab, increased immune activity and could shift tumors toward a more PD-L1-positive phenotype. The study strengthened biological plausibility rather than providing registrational efficacy evidence.

BRACELET-1

BRACELET-1 randomized patients with HR-positive/HER2-negative advanced or metastatic breast cancer to paclitaxel-based arms. In the final 2024 analysis, the company reported:

• Median PFS of 12.1 months with pelareorep + paclitaxel versus 6.4 months with paclitaxel.
• Confirmed ORR of 37.5% versus 13.3%.
• Two-year overall survival of 64% versus 33%.
• Median OS not reached in the pelareorep arm at the protocol-defined end of follow-up; the company provided a conservative estimate of at least 32.1 months versus 18.2 months in the control arm.

These are important randomized signals, but BRACELET-1 was not a pivotal trial and its sample size was limited. Oncolytics has not launched the previously discussed registration-enabling breast study with internal funds. The most realistic near-term value is therefore through a license, partnership or broader strategic transaction.

Evidence hierarchy: separating proof, signal and company interpretation

Oncolytics has a large volume of clinical material, but not every data point carries the same weight. A disciplined review should rank the evidence rather than count press releases.

What Fast Track means—and what it does not

Financial position: near-term milestones funded through equity, not a durable runway

Oncolytics’ financial profile is the principal counterweight to its clinical and regulatory momentum. The company is pre-revenue, has accumulated losses since inception and must fund clinical operations, manufacturing, regulatory work and public-company costs before any approval is possible.

Why the cash balance rose despite a large operating burn

During Q1 2026, Oncolytics sold 7,446,574 shares through an ATM program for $7.86 million gross and $7.61 million net. From April 1 through May 12, the company sold another 2,575,905 shares under the new Jefferies agreement for $2.36 million gross and $2.29 million net. Financing activity therefore replaced cash consumed by operations.

Capital structure and dilution risk

Oncolytics has used equity issuance as its principal financing tool. This does not automatically invalidate the clinical thesis—most small clinical-stage biotechs require repeated financing—but it changes the per-share economics. A successful asset can create value while existing holders still experience substantial ownership dilution if development is financed at low prices.

From December 31, 2024 to May 12, 2026, the outstanding share count increased by approximately 49.2%. From December 31, 2025 to May 12, 2026, it increased about 10.5%. These calculations measure share-count expansion, not total economic dilution from every potentially issuable security.

ATM capacity

On April 6, 2026, Oncolytics entered an open-market sale agreement with Jefferies allowing sales of up to $75 million of common stock. The facility is capacity, not cash already received. The number of shares ultimately issued depends on usage and market prices. A higher share price can reduce the number of shares required to raise a given amount; a lower price has the opposite effect.

Options, warrants and equity awards

At March 31, 2026, the diluted loss-per-share table excluded approximately 30.4 million anti-dilutive securities: 8.20 million warrants, 18.58 million options and 3.61 million RSUs/incentive awards. They were excluded from accounting dilution because the company reported a loss, but some could become economically relevant if vesting conditions are met or the share price rises above exercise prices.

The 2025 filing also describes transaction-related performance awards, including a potential CEO award based on a percentage of outstanding shares and a Chief Business Officer award tied to an acquisition or exclusive license transaction. Such incentives can align management with a strategic outcome, but they also create potential dilution and are not evidence that a deal is imminent.

Intellectual property, manufacturing and partnerships

Manufacturing readiness

Biologic and viral therapies can fail commercially even after good clinical data if manufacturing is inconsistent, expensive or insufficiently validated. Oncolytics reported that it had enough drug product for its clinical development program and was preparing drug-substance and fill/finish processes for validation and commercial readiness. In 2025 it completed cGMP production activity and work with a secondary fill/finish supplier.

New U.S. manufacturing patent

In June 2026, the USPTO issued a patent covering the company’s proprietary commercial manufacturing process for pelareorep, which Oncolytics expects to provide protection into 2044. The company has also filed a method-of-use application that, if granted and maintained, is expected to extend protection into 2046. The method-of-use application was pending at the data cut-off and should not be treated as an issued patent.

Patent duration does not eliminate competition, validity challenges, design-around risk or regulatory exclusivity questions. It does, however, address a material weakness common to older biotechnology assets: the risk that core composition or process protection expires before commercialization becomes realistic.

PanCAN and strategic collaborations

The Pancreatic Cancer Action Network award provides up to $5 million in eligible support for the randomized GOBLET pancreatic cohort. At March 31, 2026, Oncolytics reported a $917,000 PanCAN receivable related to eligible spending and recognized $390,000 as a reduction of Q1 R&D expense.

The company also has an exclusive regional licensing arrangement with Adlai Nortye covering territories including China, Hong Kong, Macau, Singapore, South Korea and Taiwan. The agreement can generate development, regulatory and commercial economics, but it has not transformed Oncolytics into a self-funding company.

Partnership strategy

Oncolytics repeatedly states that it is pursuing partnerships to accelerate development. The strongest obvious packages are:

• Pancreatic cancer: a defined FDA-aligned Phase 3 concept requiring funding and potentially checkpoint supply.
• Metastatic breast cancer: two randomized studies plus translational data, but no active registration-enabling trial.
• Anal cancer: Fast Track and a potentially efficient rare-cancer pivotal path, still requiring protocol execution and capital.
• RAS combinations: early preclinical platform extension that could interest targeted-therapy partners if additional data are convincing.

Management, execution and governance

The leadership profile changed materially in 2025–2026. The current team combines long-standing pelareorep knowledge with newer executives associated with late-stage operations and biotechnology transactions.

Execution positives

• The company moved from a broad program set toward two clearer registration-focused indications.
• REO 033 was launched quickly after colorectal Fast Track.
• FDA interactions in colorectal and anal cancer have been frequent and strategically relevant.
• Manufacturing, patent and operating leadership received attention before pivotal development.

Governance and cost questions

Q1 2026 G&A expense rose to $4.73 million, including higher public-company and personnel-related costs. Stock-based compensation and consultant shares contributed to the expense and share count. The company must demonstrate that a larger leadership and advisory structure produces faster trial execution, regulatory clarity or partnerships rather than simply increasing overhead.

In July 2026, the board changed the company’s auditor from Ernst & Young to Baker Tilly in connection with corporate restructuring. The 8-K stated that there were no accounting disagreements or reportable events associated with the change. Prior audit reports included going-concern explanatory language, which reflects the financing position rather than an auditor dispute.

Ownership

The 2025 Form 10-K, using information available around March 23, 2026, identified Anson-related entities as beneficial owners of approximately 7.65 million shares, or 6.18%. Current executive officers and directors as a group beneficially owned approximately 4.42 million shares, or 3.67%, including options exercisable within 60 days. Ownership percentages can change rapidly when the company issues shares.

Future catalyst calendar

Bull, base and bear scenarios

Red flags, falsifiers and monitoring checklist

Clinical and scientific risks

• Small datasets: the most exciting CRC and SCAC figures come from limited patient numbers.
• Historical-control bias: cross-trial comparisons can exaggerate apparent benefit.
• Combination attribution: several regimens include chemotherapy and checkpoint inhibitors, making pelareorep’s individual contribution difficult to isolate without randomized evidence.
• Endpoint uncertainty: response rate may not translate into PFS or OS, while survival-tail hypotheses require long follow-up.
• Cross-indication assumptions: positive breast or pancreatic biology does not guarantee colorectal or anal cancer success.

Regulatory and execution risks

• FDA meeting outcomes can be more demanding than company expectations.
• Accelerated approval standards have become more evidence-intensive and still require confirmatory obligations.
• Small-cap oncology studies can be delayed by contracting, site activation, competing trials and strict eligibility criteria.
• The anal pivotal study has no confirmed public start date, sample size or funding package at the data cut-off.
• The pancreatic Phase 3 cannot be treated as active without a partner.

Financial and capital-market risks

• Going-concern disclosure and cash needs create continuous financing sensitivity.
• The $75 million ATM capacity is large relative to the company’s historical cash balance and share base.
• Warrants, options, RSUs and transaction awards add potential future dilution.
• High stock volatility can change the economics of financing quickly.
• A partnership may be non-dilutive in cash terms but can transfer substantial territorial or product economics.

Retail sentiment: the narrative around $ONCY

Retail discussion around ONCY tends to divide into two strong narratives. Bullish traders focus on the number of FDA Fast Track designations, durable responses, complete responses in anal cancer, the apparent survival tail across studies, transaction-experienced management and the possibility of a partnership or acquisition. Bearish traders focus on the long corporate history without an approved product, repeated financing, historical-control comparisons, changing lead indications and the gap between an FDA-aligned concept and a fully funded pivotal program.

This sentiment is useful for understanding volatility but not for establishing clinical value. Reddit, Stocktwits and X posts are comments from non-professional traders unless the author is independently verified. They should not be treated as evidence, and social momentum can reverse rapidly around financing disclosures or immature data.

Bottom line

Oncolytics enters the second half of 2026 with more regulatory momentum than at any recent point in its history. Pelareorep now has Fast Track designations across three gastrointestinal indications, the colorectal program is actively randomized, the anal cancer program has a defined post-standard-of-care target and the company has improved its manufacturing-IP position. The earlier breast and pancreatic evidence gives the platform more depth than a typical single-cohort micro-cap oncology story.

The company is also financially fragile. The March cash balance was below one quarter’s Q1 operating cash use, the share count has increased sharply, and the new ATM facility gives Oncolytics access to capital by transferring financing risk to current shareholders. That does not mean the company cannot succeed; it means clinical and regulatory progress must be evaluated on a per-share basis and not only as scientific progress.

The defining near-term event is the FDA discussion around REO 033 Part B, followed by the first controlled colorectal response update. If randomized evidence confirms a meaningful advantage and the FDA supports an efficient registrational design, the company’s earlier signals may begin to convert into a credible approval path. If the controlled data are weak or the path becomes much larger and more expensive, the historical datasets and Fast Track designations will not protect the equity from clinical and financing pressure.

Earlier Merlintrader coverage

These earlier articles preserve the chronology of the story before this Stock Hub. Their financial snapshots and lead-catalyst assumptions should be read in the context of the dates on which they were published.

• Oncolytics Biotech: earlier company and pipeline overview
• Oncolytics Biotech: February 2026 colorectal Fast Track follow-up

Primary sources and verification links

Company-reported clinical comparisons are identified as such throughout the report. The SEC filings, FDA pages and ClinicalTrials.gov record should be treated as the principal sources for financial, regulatory and trial-status facts.

1. July 20, 2026 anal cancer Fast Track release
2. July 13, 2026 REO 033 and Type D meeting update
3. ClinicalTrials.gov: NCT07446322 / REO 033
4. February 4, 2026 colorectal Fast Track
5. March 2, 2026 REO 033 launch
6. May 4, 2026 colorectal duration-of-response update
7. January 12, 2026 third-line anal cancer data
8. April 27, 2026 FDA alignment on anal cancer pivotal design
9. FDA: May 2025 retifanlimab approval in SCAC
10. February 24, 2026 registration-focused strategy
11. December 2022 pancreatic cancer Fast Track
12. FDA-aligned pancreatic Phase 3 design
13. GOBLET pancreatic ESMO update
14. September 2024 BRACELET-1 final results
15. April 2021 AWARE-1 primary endpoint
16. May 2017 metastatic breast cancer Fast Track
17. May 2018 FDA Special Protocol Assessment
18. June 2018 Nasdaq Capital Market listing
19. ASCO 2026 translational-data release
20. June 2026 RAS-targeted preclinical combinations
21. June 2026 manufacturing patent
22. Form 10-Q for the quarter ended March 31, 2026
23. Form 10-K for the year ended December 31, 2025
24. April 6, 2026 $75 million Jefferies ATM 8-K
25. July 2026 change in certifying accountant 8-K
26. July 2025 Nasdaq bid-price compliance
27. August 2025 voluntary TSX delisting
28. April 2026 U.S. domestication
29. June 2025 CEO appointment
30. June 2025 Chief Business Officer appointment
31. June 2026 board and COO update